Liu and co-workers reported that neddylation inhibition with MLN4924 was effective toward BCR-ABL mutational imatinib-resistant cells, and the self-renewal capacity of leukemia stem cells (LSCs) in CML. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.